BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36139650)

  • 1. Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL.
    Chi C; Harth L; Galera MR; Torrealba MP; Vadivel CK; Geisler C; Bonefeld CM; Nielsen PR; Bzorek M; Becker JC; Gjerdrum LMR; Ødum N; Woetmann A
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    Huang LH; Chung HY; Su HM
    BMC Cancer; 2017 Dec; 17(1):890. PubMed ID: 29282029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy.
    Knaneh J; Hodak E; Fedida-Metula S; Edri A; Eren R; Yoffe Y; Amitay-Laish I; Prag Naveh H; Lubin I; Porgador A; Moyal L
    Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686697
    [No Abstract]   [Full Text] [Related]  

  • 4. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.
    Kiessling MK; Oberholzer PA; Mondal C; Karpova MB; Zipser MC; Lin WM; Girardi M; Macconaill LE; Kehoe SM; Hatton C; French LE; Garraway LA; Polier G; Süss D; Klemke CD; Krammer PH; Gülow K; Dummer R
    Blood; 2011 Feb; 117(8):2433-40. PubMed ID: 21209378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic approaches for cutaneous T cell lymphomas.
    Pavlidis A; Piperi C; Papadavid E
    Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
    [No Abstract]   [Full Text] [Related]  

  • 6. Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD.
    Du X; Cai C; Yao J; Zhou Y; Yu H; Shen W
    Biochem Biophys Res Commun; 2017 Jan; 483(1):409-417. PubMed ID: 28027934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.
    Dusílková N; Bašová P; Polívka J; Kodet O; Kulvait V; Pešta M; Trněný M; Stopka T
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.
    Lin M; Kowolik CM; Xie J; Yadav S; Overman LE; Horne DA
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of cutaneous T cell lymphomas.
    Bagherani N; Smoller BR
    F1000Res; 2016; 5():. PubMed ID: 27540476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-1c.
    Teran-Garcia M; Adamson AW; Yu G; Rufo C; Suchankova G; Dreesen TD; Tekle M; Clarke SD; Gettys TW
    Biochem J; 2007 Mar; 402(3):591-600. PubMed ID: 17313375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin induction of glucokinase and fatty acid synthase in hepatocytes: analysis of the roles of sterol-regulatory-element-binding protein-1c and liver X receptor.
    Hansmannel F; Mordier S; Iynedjian PB
    Biochem J; 2006 Oct; 399(2):275-83. PubMed ID: 16834571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL).
    Gantchev J; Martínez Villarreal A; Xie P; Lefrançois P; Gunn S; Netchiporouk E; Sasseville D; Litvinov IV
    Front Oncol; 2019; 9():429. PubMed ID: 31214493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma.
    Ezzeddini R; Taghikhani M; Somi MH; Samadi N; Rasaee MJ
    Life Sci; 2019 May; 224():169-176. PubMed ID: 30914315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
    Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Breast Cancer Cell FASN Expression by Obesity-Related Systemic Factors.
    McClellan B; Pham T; Harlow B; Lee G; Quach D; Jolly C; Brenner A; deGraffenried L
    Breast Cancer (Auckl); 2022; 16():11782234221111374. PubMed ID: 36035625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
    Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
    J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.